Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report

View
Author
Date
2021-11-11Permanent link
https://hdl.handle.net/11351/7615DOI
10.3389/fendo.2021.731631
ISSN
1664-2392
WOS
000727887300001
PMID
34858324
Abstract
Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.
Keywords
Agressive pituitary tumors; Capecitabine; TemozolomideBibliographic citation
Mirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, Garcia-Alvarez A, et al. Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report. Front Endocrinol. 2021 Nov 11;12:731631.
Audience
Professionals
This item appears in following collections
- HVH - Articles científics [4476]
- VHIO - Articles científics [1250]
The following license files are associated with this item:




